- Home
- HUMAW
HUMAW
Humacyte Inc. Warrant
as 11-15-2024 4:00pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Humacyte Inc. Warrant News
HUMAW Breaking Stock News: Dive into HUMAW Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
GlobeNewswire
9 days ago
Humacyte Third Quarter 2024 Financial Results and Business Update
GlobeNewswire
11 days ago
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024
GlobeNewswire
20 days ago
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
Simply Wall St.
23 days ago
High Growth Tech Stocks to Watch in October 2024
GlobeNewswire
25 days ago
Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024
The Wall Street Journal
a month ago
‘It’s Spare Parts for People’: Blood Vessels Grown in a Lab
GlobeNewswire
a month ago
Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
Compare HUMAW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HUMAW Humacyte Inc. Warrant - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.